Log in

Relevant bibliographies by topics / RAPID3 / Journal articles

To see the other types of publications on this topic, follow the link: RAPID3.

Journal articles on the topic 'RAPID3'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'RAPID3.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Castrejón, Isabel, Maxime Dougados, Bernard Combe, Francis Guillemin, Bruno Fautrel, and Theodore Pincus. "Can Remission in Rheumatoid Arthritis Be Assessed Without Laboratory Tests or a Formal Joint Count? Possible Remission Criteria Based on a Self-report RAPID3 Score and Careful Joint Examination in the ESPOIR Cohort." Journal of Rheumatology 40, no. 4 (2013): 386–93. http://dx.doi.org/10.3899/jrheum.121059.

Full text

Abstract:

Objective.To explore 5 possible criteria for remission in rheumatoid arthritis (RA) based on a patient self-report index, the Routine Assessment of Patient Index Data (RAPID3), with a careful joint examination and possible physician global estimate (DOCGL), but without a formal joint count or laboratory test.Methods.The ESPOIR early RA cohort of 813 French patients recruited in 2002–2005 was analyzed to identify patients in remission 6 months after enrollment, according to 2 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria: Boolean ≤ 1 for total tender j

APA, Harvard, Vancouver, ISO, and other styles

2

PINCUS, THEODORE, CHRISTOPHER J. SWEARINGEN, MARTIN BERGMAN, and YUSUF YAZICI. "RAPID3 (Routine Assessment of Patient Index Data 3), a Rheumatoid Arthritis Index Without Formal Joint Counts for Routine Care: Proposed Severity Categories Compared to Disease Activity Score and Clinical Disease Activity Index Categories." Journal of Rheumatology 35, no. 11 (2008): 2136–47. http://dx.doi.org/10.3899/jrheum.080182.

Full text

Abstract:

ObjectiveTo compare 4 categories (high, moderate, and low severity, and near-remission) of RAPID3 (Routine Assessment of Patient Index Data 3), an index without formal joint counts, which is scored in < 10 seconds to 4 categories of the DiseaseActivity Score (DAS28) and Clinical Disease Activity Index (CDAI) in patients with rheumatoid arthritis (RA).MethodsAll patients complete a Multidimensional Health Assessment Questionnaire (MDHAQ) at each visit. A physician/assessor 28-joint count and erythrocyte sedimentation rate (ESR) were completed in 285 patients with RA in usual care by 3 rheuma

APA, Harvard, Vancouver, ISO, and other styles

3

Ramrattan, L. A., Z. Vaghaiwalla, S. Singh, K. Ramsubeik, M. Thway, and G. Kaeley. "AB0119 DISCORDANCE OF RAPID3 AND CDAI IN RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1088.2–1089. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1682.

Full text

Abstract:

Background:The Clinical Disease Activity Index (CDAI) and the Routine Assessment of Patient Index Data 3 (RAPID3) ascertain rheumatoid arthritis (RA) disease activity and inform treatment decisions. The CDAI has provider and patient components, whilst the RAPID3 only has patient driven measures. During the COVID-19 pandemic, telemedicine visits relied on RAPID3 as a clinical outcome measure and subsequently was incorporated into all clinical visits in addition to the CDAI. On an ad-hoc basis, discrepancies were noted for the disease activity level generated by these two measures. The purpose o

APA, Harvard, Vancouver, ISO, and other styles

4

Valls Roc, M., O. Codina Guinó, M. Sala Gomez, S. Castell Quiñones, and C. Mora Maruny. "AB1256 CORRELATION BETWEEN SERUM CALPROTECTIN LEVELS, RAPID3 AND DISEASE ACTIVITY MEASURES IN PATIENTS WITH RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1920.1–1920. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1024.

Full text

Abstract:

Background:Tight control of rheumatoid arthritis (RA) is essential and we need a validated, objective and reproducible disease measure to achieve it. There is not gold standard in RA. There is a rising interest in evaluating disease activity on the patient’s point of view using patient-reported outcomes like RAPID3. Furthermore, some new biomarkers have appeared, like serum calprotectin, with promising results on its analyzing.Objectives:To evaluate correlation between disease activity measures usually used in patients with RA (DAS28 ESR/CRP, SDAI and CDAI) and other alternative tools (RAPID3

APA, Harvard, Vancouver, ISO, and other styles

5

Huang, Huaguo. "Accelerated RAPID Model Using Heterogeneous Porous Objects." Remote Sensing 10, no. 8 (2018): 1264. http://dx.doi.org/10.3390/rs10081264.

Full text

Abstract:

To enhance the capability of three-dimensional (3D) radiative transfer models at the kilometer scale (km-scale), the radiosity applicable to porous individual objects (RAPID) model has been upgraded to RAPID3. The major innovation is that the homogeneous porous object concept (HOMOBJ) used for a tree crown scale is extended to a heterogeneous porous object (HETOBJ) for a forest plot scale. Correspondingly, the radiosity-graphics-combined method has been extended from HOMOBJ to HETOBJ, including the random dynamic projection algorithm, the updated modules of view factors, the single scattering

APA, Harvard, Vancouver, ISO, and other styles

6

Suzuki, M., N. Takahashi, Y. Sobue, et al. "AB0238 USEFULNESS OF RAPID3 IN ASSESSING UNMET NEEDS OF RHEUMATOID ARTHRITIS PATIENTS FROM THE T-FLAG STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1303.2–1304. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2604.

Full text

Abstract:

BackgroundRoutine Assessment of Patient Index Data 3 (RAPID3) is a patient-reported outcome (PRO) that can be used to assess the condition of rheumatoid arthritis (RA) patients using only a questionnaire that can be completed in a short time. It is useful as a simple method for assessing disease activity. In previous reports, RAPID3 could be used as an assessment similar to Disease Activity Score 28 (DAS28), a common disease activity assessment [1]. However, in the treatment of RA, there are unmet needs in which patients have low satisfaction with treatment, even though they are in remission a

APA, Harvard, Vancouver, ISO, and other styles

7

Boone, Niels W., Alexandre Sepriano, Paul-Hugo van der Kuy, Rob Janknegt, Ralph Peeters, and Robert B. M. Landewé. "Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice." RMD Open 5, no. 2 (2019): e001050. http://dx.doi.org/10.1136/rmdopen-2019-001050.

Full text

Abstract:

ObjectiveTo test the longitudinal association between patient-reported outcome, Routine Assessment of Patient Index Data 3 (RAPID3) and the Disease Activity Score in 28 joints that includes the erythrocyte sedimentation rate (DAS28-ESR) in routine-care patients with rheumatoid arthritis (RA).MethodsPatients with RA treated with disease-modifying antirheumatic drugs were included in this prospective observational cohort. The longitudinal association between RAPID3 (0–10) and DAS28-ESR and its individual components (swollen joint count (SJC), erythrocyte sedimentation rate (ESR) (mm/hour), tende

APA, Harvard, Vancouver, ISO, and other styles

8

Wiegel, J., B. Seppen, M. Ter Wee, M. Boers, M. Nurmohamed, and W. H. Bos. "POS1480-HPR SCREENING WITH THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 QUESTIONNAIRE CAN REDUCE THE NUMBER OF CLINIC VISITS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1086.1–1086. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2592.

Full text

Abstract:

BackgroundThe long-term and frequent evaluation of disease activity in patients with rheumatoid arthritis (RA) leads to a large burden of planned consultations at outpatient clinics. It might be possible to reduce that burden by prescreening to identify patients with low disease activity with the electronic Routine Assessment of Patient Index Data 3 (RAPID3), with the aim to let them skip their visits. For this purpose, accurate classification of patients in the low category with the RAPID3 is required.ObjectivesTo evaluate the test characteristics and agreement between the Disease Activity Sc

APA, Harvard, Vancouver, ISO, and other styles

9

Carrol, Matthew B. "The QuickDASH in the Assessment of Rheumatoid Arthritis Disease Activity." Osteology and Rheumatology – Open Journal 1, no. 2 (2016): 23–29. http://dx.doi.org/10.17140/orhoj-1-108.

Full text

Abstract:

Introduction: Rheumatoid Arthritis (RA) is a chronic inflammatory arthritis associated with substantial morbidity and mortality. Disease activity indices help guide therapy towards disease remission. This study studied whether the modified version of the Disabilities of Arm, Shoulder, and Hand (DASH), the QuickDASH, was valid in measuring RA disease activity. Methods: This prospective cohort study evaluated the performance of the QuickDASH in measuring RA disease activity as compared with the validated index, the Routine Assessment of Patient Index Data 3 (RAPID3). Both questionnaires were com

APA, Harvard, Vancouver, ISO, and other styles

10

PINCUS, THEODORE, PATRICIA HINES, MARTIN J. BERGMAN, YUSUF YAZICI, LISA C. ROSENBLATT, and ROSS MacLEAN. "Proposed Severity and Response Criteria for Routine Assessment of Patient Index Data (RAPID3): Results for Categories of Disease Activity and Response Criteria in Abatacept Clinical Trials." Journal of Rheumatology 38, no. 12 (2011): 2565–71. http://dx.doi.org/10.3899/jrheum.110262.

Full text

Abstract:

Background.An index is needed to assess the status of patients with rheumatoid arthritis (RA), as none of the existing measures are applicable to all individual patients. The 28-joint Disease Activity Score (DAS28) is the most specific and widely used index. Routine Assessment of Patient Index Data (RAPID3) is an index containing only the 3 patient self-report core dataset measures, without a laboratory test or formal joint count, and with simple scoring. RAPID3 is correlated significantly with DAS28, but calculated in 5–10 seconds on a Multidimensional Health Assessment Questionnaire (MDHAQ),

APA, Harvard, Vancouver, ISO, and other styles

11

Inciarte-Mundo, J., R. Morlà, B. Frade-Sosa, et al. "FRI0042 DISCREPANCIES BETWEEN RAPID3 AND DAS28 IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION OR LOW DISEASE ACTIVITY RECEIVING TNF INHIBITORS: WHAT IS THE ROLE OF THE INFLAMMATION BIOMARKERS?" Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 596.1–596. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5516.

Full text

Abstract:

Background:Patients and Rheumatologist often differ in their perception of RA disease activity. Remission or low disease activity should be the treatment target in RA, patients should be included in treatment decisions.Objectives:To identify factors influencing patient’s self-reported disease activity by RAPID3 test.Methods:47 RA patients in remission or low disease activity by DAS28ESR (DAS28ESR ≤ 3.2) receiving TNFi (etanercept, adalimumab and infliximab) stratified their disease activity by RAPID3, then two patients’ groups were defined:target group(RAPID3 with remission 0-3 or low disease

APA, Harvard, Vancouver, ISO, and other styles

12

ASKANASE, ANCA DINU, ISABEL CASTREJÓN, and THEODORE PINCUS. "Quantitative Data for Care of Patients with Systemic Lupus Erythematosus in Usual Clinical Settings: A Patient Multidimensional Health Assessment Questionnaire and Physician Estimate of Noninflammatory Symptoms." Journal of Rheumatology 38, no. 7 (2011): 1309–16. http://dx.doi.org/10.3899/jrheum.101091.

Full text

Abstract:

Objective.To analyze quantitative data in patients with systemic lupus erythematosus (SLE), seen in usual care, from a patient Multidimensional Health Assessment Questionnaire (MDHAQ) with routine assessment of patient index data (RAPID3) scores and from a physician global estimate of noninflammatory symptoms; and to compare results to self-report Systemic Lupus Activity Questionnaire (SLAQ) scores and 4 SLE indices: SLE Disease Activity Index-2K (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG), Systemic Lupus Activity Measure (SLAM), and European Consensus Lupus Activity Measurement

APA, Harvard, Vancouver, ISO, and other styles

13

Coates, L., A. Kavanaugh, E. Mcdearmon-Blondell, A. Mandelin, T. Gao, and W. Tillett. "POS1050 UPADACITINIB VERSUS ADALIMUMAB ON ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) IN PATIENTS WITH PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 843.2–844. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2533.

Full text

Abstract:

BackgroundRAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index that is calculated from 3 patient-reported measures: physical function, pain, and patient global assessment. A fast and convenient tool, RAPID3 can be easily used in clinical practice and is applicable to multiple rheumatic diseases, including psoriatic arthritis (PsA), and was shown to correlate with other clinical composite measures of disease activity1. Here, we assessed the long-term effect of upadacitinib (UPA), an oral JAK inhibitor, and adalimumab (ADA) on RAPID3 scores in patients with PsA via a p

APA, Harvard, Vancouver, ISO, and other styles

14

Bergman, M., M. H. Buch, Y. Tanaka, et al. "POS0670 ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH LONG-TERM UPADACITINIB THERAPY." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 579. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2090.

Full text

Abstract:

Background:Routine Assessment of Patient Index Data 3 (RAPID3) is a pooled index of 3 patient-reported measures: patient global assessment, pain, and physical function. RAPID3 was shown to correlate with other composite measures of disease activity1 and is recommended by the American College of Rheumatology for use in clinical practice.2Objectives:To evaluate the impact of upadacitinib (UPA) versus comparators on RAPID3 over 60 weeks, as well as the correlation of RAPID3 scores with other disease measures in the UPA phase 3 SELECT clinical program.Methods:This post hoc analysis included placeb

APA, Harvard, Vancouver, ISO, and other styles

15

Amaya-Amaya, Jenny, Diana Botello-Corzo, Omar-Javier Calixto, et al. "Usefulness of Patients-Reported Outcomes in Rheumatoid Arthritis Focus Group." Arthritis 2012 (September 28, 2012): 1–13. http://dx.doi.org/10.1155/2012/935187.

Full text

Abstract:

Objective. Patient-reported outcomes (PROs) have become an essential part of the assessment of patients with rheumatoid arthritis (RA). We aimed to evaluate the agreement and correlation between PROs and the physician's measurements. Methods. This was a cross-sectional analytical study in which 135 patients with RA were clinically evaluated during two different sessions of focus group interviews. Rheumatologist recorded 28 swollen (SJCs) and tender joint counts (TJCs). The patients filled out the PROs instruments (MDHAQ, RADAI, RAPID3, 4, and 5 and self-report articular index (SAI) diagram for

APA, Harvard, Vancouver, ISO, and other styles

16

Walsh, Jessica A., Marilyn T. Wan, Christine Willinger, et al. "Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease." Journal of Rheumatology 47, no. 10 (2019): 1496–505. http://dx.doi.org/10.3899/jrheum.190219.

Full text

Abstract:

ObjectiveTo examine the construct validity of Routine Assessment of Patient Index Data 3 (RAPID3) and Psoriatic Arthritis Impact of Disease (PsAID) in patients with psoriatic arthritis (PsA). In examining construct validity, we also addressed scores among subgroups with severe psoriasis, poly articular disease, enthesitis, and dactylitis, and evaluated influences of sociodemographic factors and comorbidities (contextual factors) on these patient-reported outcomes (PRO).MethodsPatients with PsA were enrolled in the Psoriatic Arthritis Research Consortium (PARC) between 2014 and 2016. PARC is a

APA, Harvard, Vancouver, ISO, and other styles

17

Eow, L. H., J. Yew, K. H. Lee, et al. "POS1460-HPR MYRA TOUCH FOR DISEASE ACTIVITY EVALUATION IN RHEUMATOID ARTHRITIS: A COMPARISON OF PATIENT-REPORTED OUTCOMES WITH PHYSICIAN’S ASSESSMENT." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1015.1–1015. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1813.

Full text

Abstract:

Background:Patient-reported outcomes (PROs) have become an essential component of patients’ assessment in the management of Rheumatoid Arthritis(RA).They have been reported to be at least as informative if not more than physician assessed outcomes.MyRA Touch was pioneered by the Rheumatology Unit of Hospital Tuanku Jaa’far in Seremban Malaysia in March 2018,to engage and empower all RA patients on their own disease activity monitoring. It is an electronic platform, designed to enhanced the application of electronic patient reported outcomes (ePROs) among RA patients where they examine and reco

APA, Harvard, Vancouver, ISO, and other styles

18

Bergman, M., Y. Tanaka, G. Citera, et al. "THU0192 UPADACITINIB TREATMENT AND THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) AMONG PATIENTS WITH RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 315.1–316. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1261.

Full text

Abstract:

Background:Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 vs JAK2, JAK3, and TYK2, and is currently being assessed for the treatment of RA. RAPID3 is a pooled index of the three key patient-reported measures: patient global assessment, pain, and physical function.Objectives:In this analysis we assessed the effect of UPA treatment on RAPID3 in the SELECT-BEYOND, SELECT-COMPARE, and SELECT-MONOTHERAPY trials.Methods:In SELECT-BEYOND1, bDMARD-IR pts received UPA 15 mg or 30 mg once daily (QD), or PBO for 12 wks while continuing stable csDMARD th

APA, Harvard, Vancouver, ISO, and other styles

19

Ahmed, F., A. Ogdie, R. Fitzsimmons, D. Shin, and J. Takeshita. "AB0922 Psoriatic Arthritis Disease Activity Differs by Race/Ethnicity." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1590.1–1590. http://dx.doi.org/10.1136/annrheumdis-2022-eular.212.

Full text

Abstract:

BackgroundPsoriatic arthritis (PsA) affects up to 30% of individuals with psoriasis. Studies have demonstrated that the presenting disease severity and quality of life impact of psoriasis differs by race/ethnicity in patients with and without PsA, but little is known about disease activity among different racial/ethnic groups [1-3].ObjectivesThe objective of our study was to evaluate disease activity by race/ethnicity among patients with PsA.MethodsWe performed a cross-sectional study of adult (≥18 years old) patients with PsA who had at least one outpatient visit within the University of Penn

APA, Harvard, Vancouver, ISO, and other styles

20

Desai, Sonali, Emma Stevens, Srinivas Emani, Peter Meyers, Maura Iversen, and Daniel H. Solomon. "Improving Quality of Care in Rheumatoid Arthritis Through Mobile Patient-Reported Outcome Measurement: Focus Group Study." JMIR Formative Research 4, no. 3 (2020): e15158. http://dx.doi.org/10.2196/15158.

Full text

Abstract:

Background Patient-reported outcomes (PROs) for chronic disease management can be integrated into the routine workflow by leveraging mobile technology. Objective The objective of our study was to describe the process of our quality improvement (QI) efforts using tablets for PRO collection in a busy, academic rheumatology practice to support a treat-to-target (TTT) approach for rheumatoid arthritis (RA) management. Methods Our QI team designed a process for routine collection of PROs for RA patients at the Arthritis Center, employing information technology and an electronic medical record (EMR)

APA, Harvard, Vancouver, ISO, and other styles

21

Berthelot, Jean-Marie, Karen Batard, Benoît le Goff, and Yves Maugars. "Forces et faiblesses du score RAPID3." Revue du Rhumatisme 79, no. 5 (2012): 379–81. http://dx.doi.org/10.1016/j.rhum.2012.02.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kohan, M. P., M. A. Medina, S. B. Papasidero, R. Chaparro del Moral, O. L. Rillo, and J. A. Caracciolo. "Desempeño del RAPID3 en pacientes con osteoartritis de rodilla, cadera o mano." Revista Argentina de Reumatología 28, no. 2 (2017): 11–14. http://dx.doi.org/10.47196/rar.v28i2.560.

Full text

Abstract:

RAPID3 es un cuestionario autorreportado desarrollado originalmente para valorar pacientes con AR. Recientemente fue empleado en pacientes con OA de rodillas y/o caderas con buenos resultados.Objetivo: Determinar si existe correlación entre el RAPID3 y otros cuestionarios en pacientes con OA de manos (AUSCAN), cadera y/o rodilla (WOMAC) y comparar el tiempo para su realización y cálculo.

APA, Harvard, Vancouver, ISO, and other styles

23

Seppen, B., S. Verkleij, J. Wiegel, M. Ter Wee, M. Nurmohamed, and W. H. Bos. "POS0381 ALLOCATION OF VISITS ACCORDING TO NEED: SCREENING RHEUMATOID ARTHRITIS PATIENTS WITH PATIENT REPORTED OUTCOMES." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 445.1–445. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2616.

Full text

Abstract:

BackgroundCurrently, patients with rheumatoid arthritis (RA) require frequent consultations to monitor their disease activity. However, since a majority of patients is in remission during routine follow up, it should be possible to reduce the number of consultations for them.1 Patients that are meeting their treatment goal, based on the results of their electronic patient reported outcome measures (ePROMs), could be eligible to skip their visit. Research revealed that patients who indicate to be in remission or have a low disease activity (remission/LDA) on their ePROMs, such as the routine as

APA, Harvard, Vancouver, ISO, and other styles

24

Singh, J., C. Adams, A. Frick, et al. "AB1825-HPR DECISION TO INITIATE A TUMOR NECROSIS FACTOR INHIBITOR IN RHEUMATOID ARTHRITIS UNCOUPLED FROM DISEASE ACTIVITY MEASURES." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 2144.2–2145. http://dx.doi.org/10.1136/annrheumdis-2023-eular.641.

Full text

Abstract:

BackgroundPrevious studies have demonstrated discordance between patient-based (e.g. RAPID3) and predominantly physician-based (e.g. CDAI) disease activity measures (DAMs).ObjectivesTo examine the relationship between DAMs and decision to initiate TNFi following csDMARDs.MethodsData: PIONEER-Rheumatology, an EMR and open text-extracted database specific to care given by the American Rheumatology Network. Study population: Adult RA patients who received TNFi as initial targeted synthetic or biologic DMARD treatment between Jan 2014 to Apr 2022 after csDMARDs. Assessments: CDAI, RAPID3, DAS28 (i

APA, Harvard, Vancouver, ISO, and other styles

25

Orozco, María Celeste, Emilce Edith Schneeberger, Natalia Zamora, Fernando A. Sommerfleck, Luis A. Cayetti, and Gustavo Citera. "Validación del cuestionario RAPID3 en la cohorte argentina ESPAXIA de pacientes con espondiloartritis axial." Revista Argentina de Reumatología 27, no. 4 (2016): 11–16. http://dx.doi.org/10.47196/rar.v27i4.574.

Full text

Abstract:

Introducción: El RAPID3 (Routine Assessment of Patient Index Data 3) es un cuestionario sencillo, rápido y de cálculo simple que mostró un buen rendimiento en Artritis Reumatoidea, siendo capaz de reﬂejar el estado de enfermedad y la calidad de vida en estos pacientes.Objetivo: Validar el cuestionario RAPID3 en una cohorte de pacientes con EsP axial y evaluar su asociación con otras medidas de evaluación de la enfermedad.

APA, Harvard, Vancouver, ISO, and other styles

26

Che, Hélène, Christian Roux, Adrien Etcheto, et al. "Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms." European Journal of Endocrinology 174, no. 3 (2016): 325–33. http://dx.doi.org/10.1530/eje-15-0661.

Full text

Abstract:

ObjectiveAdults with X-linked hypophosphatemia (XLH) may suffer from skeletal symptoms leading to functional disability. No data on their quality of life (QoL) have been reported so far. Our objectives were to evaluate the QoL and its determinants in XLH adults.Patients and methodsWe conducted a prospective study in XLH adults, who consulted for musculoskeletal symptoms between 2013 and 2014. We assessed their QoL using HAQ, RAPID3 and SF36, and analysed the variables associated with low QoL. We compared their QoL to that of patients affected with axial spondyloarthritis (ax-SpA) (paired on ag

APA, Harvard, Vancouver, ISO, and other styles

27

Berthelot, Jean-Marie, Karen Batard, Benoît le Goff, and Yves Maugars. "Strengths and weaknesses of the RAPID3 score." Joint Bone Spine 79, no. 6 (2012): 536–38. http://dx.doi.org/10.1016/j.jbspin.2012.03.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Biliavska, I., E. Lenguerrand, J. Tobias, and P. Hamann. "POS0475 FACTORS INFLUENCING ACCEPTANCE AND PERSISTENCE OF ELECTRONIC PATIENT-REPORTED OUTCOMES COLLECTION IN A REAL-WORLD CLINICAL SETTING." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 498.1–498. http://dx.doi.org/10.1136/annrheumdis-2023-eular.4012.

Full text

Abstract:

BackgroundRheumatoid arthritis (RA) has a relapsing-remitting nature, making it difficult to predict when patients should be seen. Collection of patient-reported outcomes (PROs) effectively communicates patients’ disease experiences. However, certain factors could impact the utilization and persistence of PROs collection.ObjectivesTo explore the impact of demographic, clinical parameters on acceptance and long-term utilization of smartphone application (app) for electronic PROs (ePROs) collection.MethodsA retrospective analysis of anonymized data collected through app as part of routine care d

APA, Harvard, Vancouver, ISO, and other styles

29

Loginova, E. Yu, T. V. Korotaeva, and A. D. Koltakova. "Use of a multidimensional RAPID3 questionnaire to assess the achievement of remission and minimal disease activity in patients with early psoriatic arthritis treated according to Treat-to-target strategy." Rheumatology Science and Practice 56, no. 6 (2019): 739–45. http://dx.doi.org/10.14412/1995-4484-2018-739-745.

Full text

Abstract:

The current Treat-to-target (T2T) strategy in the management of patients with psoriatic arthritis (PsA) is based on strict control over the dynamics of a patient's status and timely correction of therapy according to the presence or absence of remission or minimal disease activity (MDA) within 6 months after treatment initiation. The multidimensional RAPID3 questionnaire based on the patient's own opinion of his/her health status, has demonstrated its high effectiveness in assessing remission in patients with rheumatoid arthritis (RA). The possibilities of using the RAPID3 questionnaire in pat

APA, Harvard, Vancouver, ISO, and other styles

30

Ogdie, A., L. Coates, R. Acayaba DE Toledo, et al. "AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1582. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2913.

Full text

Abstract:

BackgroundPsA is a chronic, systemic inflammatory disease with diverse clinical manifestations that can impact a patients’ quality of life. Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit, is approved for the treatment of active PsA in adults. In the phase 3 KEEPsAKE 1 and 2 studies, RZB treatment resulted in significantly greater improvements in signs and symptoms of active PsA compared with placebo (PBO).1,2 RAPID3 is frequently used in clinical practice to evaluate PsA disease activity and consists

APA, Harvard, Vancouver, ISO, and other styles

31

KHAN, NASIM A., YUSUF YAZICI, JAIME CALVO-ALEN, et al. "Reevaluation of the Role of Duration of Morning Stiffness in the Assessment of Rheumatoid Arthritis Activity." Journal of Rheumatology 36, no. 11 (2009): 2435–42. http://dx.doi.org/10.3899/jrheum.081175.

Full text

Abstract:

Objective.To evaluate the utility of the duration of morning stiffness (MS), as a patient-reported outcome (PRO), in assessing rheumatoid arthritis (RA) disease activity.Methods.We acquired information on 5439 patients in QUEST-RA, an international database of patients with RA evaluated by a standard protocol. MS duration was assessed from time of waking to time of maximal improvement. Ability of MS duration to differentiate RA activity states, based on Disease Activity Score (DAS)28, was assessed by analysis of variance; and a receiver-operating characteristic (ROC) curve was plotted for disc

APA, Harvard, Vancouver, ISO, and other styles

32

Morlà, R., T. LI, G. Luta, and T. Pincus. "AB0786 Self-reported disease burden is greater in spondyloarthritis than in rheumatoid arthritis patients according to multidimensional questionnaire (MDHAQ / RAPID3) scores, despite fewer females, who generally have higher scores on patient questionnaires." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1520.1–1520. http://dx.doi.org/10.1136/annrheumdis-2022-eular.852.

Full text

Abstract:

BackgroundFemale patients generally have higher scores than males on most items on self-report questionnaires, including MDHAQ/RAPID3 (multi-dimensional health assessment questionnaire/routine assessment of patient index data)1. MDHAQ/RAPID3 was validated in patients with rheumatoid arthritis (RA), but is informative in all diseases studied, including spondyloarthritis (SpA)2. More SpA patients are men than RA patients, suggesting lower scores, but MDHAQ scores are higher in SpA than RA.ObjectivesWe compared self-report MDHAQ/RAPID3 scores in RA vs SpA patients according to gender.MethodsPatie

APA, Harvard, Vancouver, ISO, and other styles

33

Boone, Niels W., Alexandre Sepriano, Paul-Hugo van der Kuy, Rob Janknegt, Ralph Peeters, and Robert B. M. Landewé. "Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time." RMD Open 5, no. 1 (2019): e000836. http://dx.doi.org/10.1136/rmdopen-2018-000836.

Full text

Abstract:

ObjectivesWe aimed to evaluate the effects of methotrexate (MTX) comedication added to biological disease-modifying antirheumatic drugs (bDMARD) on disease activity measures in patients with rheumatoid arthritis (RA) in routine care.MethodsPatients with RA on treatment with either bDMARDs or conventional synthetic DMARDs were included in this prospective cohort study. The effect of (time-varying) combination therapy with bDMARD and MTX compared with bDMARD monotherapy was tested in longitudinal generalised estimating equation models using as outcomes: (1) the likelihood to be in remission acco

APA, Harvard, Vancouver, ISO, and other styles

34

Pincus, T., and N. Steen Krogh. "FRI0587 A NEW APPROACH TO EARLY DETECTION OF ADVERSE EVENTS OF HIGH-RISK MEDICATIONS USING A STRUCTURED, STANDARD, PROTOCOL DRIVEN WEEKLY REMOTE ELECTRONIC MDHAQ 60-SYMPTOM CHECKLIST." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 898–99. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4942.

Full text

Abstract:

Background:A multidimensional health assessment questionnaire (MDHAQ) includes RAPID3, which distinguishes active from control treatments in rheumatoid arthritis clinical trials, and documents change comparably to disease-specific indices in all diseases studied. The MDHAQ also includes a standard, structured 60-symptom checklist, to recognize comorbidities, provide a review of systems, and serve on a fibromyalgia assessment screening tool (FAST3) as a clue to identify patients with fibromyalgia. A new MDHAQ application is to recognize adverse events to high-risk medications on a standard, str

APA, Harvard, Vancouver, ISO, and other styles

35

Watson, H., J. Del Valle Mendoza, W. Silva Caso, et al. "POS0532 GLOBAL ULTRASOUND SYNOVITIS SCORE MAY REFLECT DEVELOPMENT OF CHRONIC POST-CHIKUNGUNYA RHEUMATISM." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 530.2–530. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2634.

Full text

Abstract:

BackgroundChronic musculoskeletal (MSK) symptoms such as arthralgia and arthritis develop in up to half of patients after acute chikungunya virus (CHIKV) infection. While MSK complaints are common during the acute infection, chronic post-CHIKV rheumatism represents a more severe outcome and is usually assessed by joint counts, laboratory markers and patient-reported outcomes (PROs). Ultrasound (US) may be a practical tool for predicting and confirming the development of chronic CHIKV.ObjectivesTo evaluate the clinical relevance of MSKUS findings in post-chikungunya rheumatism.Methods80 patient

APA, Harvard, Vancouver, ISO, and other styles

36

Fedkov, Dmytro, Christine Peine, Abdullah Khalil, and Felix Lang. "Disease activity and fatigue in inflammatory arthritis patients with different dietary preferences: a retrospective exploratory cross-sectional study." Rheumatology 62, no. 3 (2024): 161–68. http://dx.doi.org/10.5114/reum/190272.

Full text

Abstract:

IntroductionRecently, diet has received considerable attention as an important factor in inflammatory arthritis. The objective of this study was to evaluate disease activity and fatigue in patients with rheumatoid arthritis and spondyloarthritis (including psoriatic arthritis) depending on their dietary preferences.Material and methodsWe retrospectively evaluated data of 774 patients collected by the Mida Rheuma App from January 2022 to December 2022. We assessed demographic parameters, major dietary patterns, and food groups (dairy products, fruits, vegetables, processed meat, meat, oily fish

APA, Harvard, Vancouver, ISO, and other styles

37

Gomez-Centeno, A. D., E. Graell Martin, H. Costa Ventura, M. Arevalo, M. García Manrique de Lara, and M. Larrosa Padro. "AB0233 RAPID3 Utility in a Spanish Rheumatoid Arthritis Clinic:." Annals of the Rheumatic Diseases 74, Suppl 2 (2015): 969.2–969. http://dx.doi.org/10.1136/annrheumdis-2015-eular.6380.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Qorolli, M., H. Hundozi-Hysenaj, and S. Grazio. "RAPID3 as toll in prediction of hand function in RA." Physiotherapy 102 (November 2016): e185. http://dx.doi.org/10.1016/j.physio.2016.10.222.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Castrejon, Isabel, Annie Huang, Sarah L. Everakes, Ailda Nika, and Winston Sequeira. "Clinical Improvement According to RAPID3 in Patients With Polymyalgia Rheumatica." JCR: Journal of Clinical Rheumatology 24, no. 7 (2018): 390–92. http://dx.doi.org/10.1097/rhu.0000000000000701.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Uhlig, Till, Elisabeth Lie, Vibeke Norvang, et al. "Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study." Journal of Rheumatology 43, no. 4 (2016): 716–23. http://dx.doi.org/10.3899/jrheum.151132.

Full text

Abstract:

Objective.To examine the frequency of 6 definitions for remission and 4 definitions for low disease activity (LDA) after starting a disease-modifying antirheumatic drug (DMARD) in patients with rheumatoid arthritis (RA) in clinical practice, and to study whether predictors for achieving remission after 6 months are similar for these definitions.Methods.Remission and LDA were calculated according to the 28-joint Disease Activity Score (DAS28), the Clinical Disease Activity Index (CDAI), the Simplified Disease Activity Index (SDAI), the Routine Assessment of Patient Index Data (RAPID3), and both

APA, Harvard, Vancouver, ISO, and other styles

41

Yokogawa, Naoto, Tetsuji Kaneko, Yoshiki Nagai, et al. "Validation of RAPID3 using a Japanese version of Multidimensional Health Assessment Questionnaire with Japanese rheumatoid arthritis patients: Characteristics of RAPID3 compared to DAS28 and CDAI." Modern Rheumatology 25, no. 2 (2014): 264–69. http://dx.doi.org/10.3109/14397595.2014.948587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Schroeder, K., T. Pincus, and M. Bergman. "AB1194 STRIKING DIFFERENCES IN THE COURSE OF OSTEOARTHRITIS (OA) COMPARED TO RHEUMATOID ARTHRITIS (RA) OVER THE FIRST 24 MONTHS OF RHEUMATOLOGY CARE AT ONE PRIVATE PRACTICE SETTING." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1887.2–1888. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3840.

Full text

Abstract:

Background:Recent reports indicate that disease burden in osteoarthritis (OA) is similar to or greater than in rheumatoid arthritis (RA) when an identical measure is used to assess patients with either disease, generally an MDHAQ/RAPID3 (multidimensional health assessment questionnaire/routine assessment of patient index data). The data suggest that a traditional view that RA is more severe than OA no longer is valid at this time. One concern is that similar disease burdens in OA vs RA may result entirely from superior treatments for RA, and RA may be considerably more severe than OA at initia

APA, Harvard, Vancouver, ISO, and other styles

43

Germain, Guillaume, Karen Worley, Sean D. MacKnight, et al. "Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count." Lupus Science & Medicine 11, no. 1 (2024): e001111. http://dx.doi.org/10.1136/lupus-2023-001111.

Full text

Abstract:

ObjectiveTo investigate the real-world impact of intravenous belimumab treatment among patients with SLE using rheumatoid arthritis-derived disease activity measures and SLE-related laboratory values.MethodsThis retrospective cohort study used US electronic medical record data from the United Rheumatology Normalised Integrated Community Evidence (UR-NICE) database. Adult patients with SLE who initiated intravenous belimumab between 1 January 2012 and 3 December 2019 (index), had 12 months of pre-index and 24 months of post-index clinical activity, and had ≥6 infusions of belimumab during the 2

APA, Harvard, Vancouver, ISO, and other styles

44

Annapureddy, N., D. Giangreco, H. Devilliers, J. A. Block, and M. Jolly. "Psychometric properties of MDHAQ/RAPID3 in patients with systemic lupus erythematosus." Lupus 27, no. 6 (2018): 982–90. http://dx.doi.org/10.1177/0961203318758503.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Zurita, María Fernanda, Adriana Iglesias, Emanuel Vanegas, Adriana Luzuriaga, and Luis Zurita. "Measurement of Disease Activity in Ecuadorian Patients with Rheumatoid Arthritis: Does RAPID3 Correlate with Traditional Indexes?" Scientific World Journal 2019 (March 20, 2019): 1–7. http://dx.doi.org/10.1155/2019/6940401.

Full text

Abstract:

Objective. The aim of this study is to demonstrate if routine assessment of patient index data 3 has a correlation with disease’s activity as much as disease activity score 28, clinical disease activity index, and simplified disease activity index in Ecuadorian patients with rheumatoid arthritis seen in Unidad de Enfermedades Reumáticas y Autoinmunes [UNERA] from December 2016 to December 2017. Methods. This is a retrospective study in 200 patients that fulfill the American College of Rheumatology 2010 criteria for diagnosis of rheumatoid arthritis. The patients were evaluated from December 20

APA, Harvard, Vancouver, ISO, and other styles

46

Giollo, A., E. Bertoldo, C. Benini, et al. "POS1173 A SHORT DELAY IN ARTHRITIS CARE IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY - LESSONS FROM THE CORONAVIRUS DISEASE 19 (COVID-19) PANDEMIC." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 867.1–867. http://dx.doi.org/10.1136/annrheumdis-2021-eular.737.

Full text

Abstract:

Background:Although disease activity is a significant outcome in rheumatology, few studies have investigated the relationship between routine care of rheumatic conditions and disease activity control.Objectives:To determine the association between delay in routine care of chronic inflammatory arthritides (CIAs) and disease activity during the first wave of coronavirus disease 19 pandemic in Verona, Italy.Methods:This study enrolled patients with an established diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and undifferentiated arthritis (UA). Bet

APA, Harvard, Vancouver, ISO, and other styles

47

Kim, Seong-Kyu, Sung-Hoon Park, Jisuk Bae, Jung Tae Son, and Jung-Yoon Choe. "Performance of Routine Assessment of Patient Index Data 3 (RAPID3) for assessment of rheumatoid arthritis in clinical practice: differential agreement of RAPID3 according to disease activity categories." Rheumatology International 34, no. 9 (2014): 1311–18. http://dx.doi.org/10.1007/s00296-014-3042-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Qorolli, Merita, Hajrije Hundozi-Hysenaj, Sylejman Rexhepi, Blerta Rehxepi, and Simeon Grazio. "RAPID3 scores and hand outcome measurements in RA patients: a preliminary study." Clinical Rheumatology 36, no. 6 (2016): 1379–85. http://dx.doi.org/10.1007/s10067-016-3514-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Ogdie, A., M. E. Husni, J. Scher, E. Craig, S. Reddy, and J. A. Walsh. "SAT0434 MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN OUTCOME MEASURES FOR USE IN CLINICAL CARE AND PRAGMATIC TRIALS IN PsA." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1173.1–1174. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3321.

Full text

Abstract:

Background:While several outcome measures have been studied for use in clinical studies of psoriatic arthritis, little is known about thresholds of meaning such as minimal clinically important improvement (MCII).Objectives:To investigate the distribution of scores for candidate outcome measures for pragmatic trials in PsA and to calculate the MCII for each outcome measure.Methods:We performed a longitudinal cohort study within the Psoriatic Arthritis Research Consortium (PARC), a multi-center study based in the US. Patients completed validated PROs (patient reported outcomes) and rheumatologis

APA, Harvard, Vancouver, ISO, and other styles

50

Yoon, Hwi-Joong, Ji Yoon Kim, Ki Young Yoo, et al. "Validation and Reliability Study for the Korean Version of the Haemophilia Activity List." Blood 128, no. 22 (2016): 5969. http://dx.doi.org/10.1182/blood.v128.22.5969.5969.

Full text

Abstract:

Abstract Background: There has been increasing interest in the patients perspective on the outcome of the treatment. The Haemophilia Activity List (HAL) has been developed as a disease-specific questionnaire for haemophilia patients and is a validated self-report measure of function developed according to WHO International Classification of Functioning, Disability and Health. In this study, we performed a cross-cultural adaptation and linguistic validation of the HAL questionnaire to assess the health-related quality of life in Korean hemophilia patients in the future. Methods: To validate HAL

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!